Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the advisory committee on immunization practices, 2015

Morbidity and Mortality Weekly Report

Volumn 64, Issue 41, 2015, Pages 1171-1176

  MacNeil, Jessica R ^a   Rubin, Lorry ^b   Folaranmi, Temitope ^a,c   Ortega Sanchez, Ismael R ^a   Patel, Manisha ^a   Martin, Stacey W ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADVISORY COMMITTEE; CHILD; HUMAN; IMMUNIZATION; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; STANDARDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADVISORY COMMITTEES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; HUMANS; IMMUNIZATION; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; YOUNG ADULT;

EID: 84947441085     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6441a3     Document Type: Note

References (20)

1. Accelerated approval of new drugs for serious or life-threatening illnesses, 21 C.F.R. Sect. 314.500 (2015). Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8
2. Bhuyan P, Eiden J, Jones TR, et al. Immunogenicity of human papilloma vaccine coadministered with an investigational bivalent rLP2086 vaccine against meningococcal serogroup B in healthy adolescents. Philadelphia, PA: IDWeek; 2014. Available at http://www.ofid.oxfordjournals.org/content/1/suppl_1/S317.2.full?sid=25a2b12f-c211-4ecc-bb47-e6ceba7bb4a2
3. Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12:597-607.
4. Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc; 2015. Available at http://jpids.oxfordjournals.org/content/early/2015/08/03/jpids.piv039.full.
5. Vesikari T, Wysocki J, Kieninger D, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine to healthy adolescents. In: Proceedings of the 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases; May 6-16, 2014, Dublin, Ireland.
6. Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine 2015;33:2500-10.
7. Perrett KP, McVernon J, Richmond PC, et al. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine 2015;33:5217-24.
8. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123-31.
9. Santolaya ME, O’Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013;9:2304-10.
10. Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
11. Advisory Committee on Immunization Practices (ACIP). Evidence-based recommendations-GRADE. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at http://www.cdc.gov/vaccines/acip/recs/GRADE/about-grade.html.
12. Advisory Committee on Immunization Practices (ACIP). GRADE evidence tables-recommendations in MMWR. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at http://www.cdc.gov/vaccines/acip/recs/GRADE/table-refs.html.
13. Food and Drug Administration. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease. Washington, DC: Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM248586.pdf.
14. Costa I, Pajon R, Granoff DM. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio 2014;5:e01625-14.
15. Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT. Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine. J Infect Dis 2015;212:784-92.
16. Food and Drug Administration. Trumenba Biologics license application. Washington, DC: Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM424626.pdf.
17. Food and Drug Administration. Bexsero Biologics license application. Washington, DC: Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM434714.pdf.
18. Food and Drug Administration. Trumenba US package insert. Washington, DC: Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf.
19. Food and Drug Administration. Bexsero US package insert. Washington, DC: Food and Drug Administration; 2015. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf.
20. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:608-12.